Relovair
GSK and Theravance file COPD drug
July 16, 2012Research and Development, Sales and Marketing EMA, GSK, Relovair, Revlar, Spiriva, Theravance
GlaxoSmithKline and US biopharma firm Theravance have submitted their investigational chronic obstructive pulmonary disease (COPD) drug to regulators in Europe …
Boehringer’s COPD drug passes hurdle
May 23, 2012Research and Development, Sales and Marketing Boehringer, COPD, Daxas, Relovair, Spiriva, olodaterol
Boehringer Ingelheim’s once-daily bronchodilator olodaterol has improved lung function versus placebo in a Phase II trial. The manufacturer wants the …
GSK buys more of Theravance
May 18, 2012Research and Development, Sales and Marketing COPD, Cellzome, GSK, Relovair, Theravance
GlaxoSmithKline now owns more than a quarter of biopharma company Theravance after shelling out nearly $213 million to buy ten …
Underwhelming results for GSK’s Relovair
January 10, 2012Research and Development, Sales and Marketing Advair, COPD, GSK, Relovair, Seretide, asthma
GlaxoSmithKline says it is on track to file its respiratory drug Relovair in Europe and the US despite mixed results …
Extra phase II studies boost GSK’s Relovair
September 23, 2010COPD, GlaxoSmithKline, Relovair, asthma
GlaxoSmithKline has conducted additional phase II trials on its asthma/COPD drug Relovair to answer a number of safety and efficacy …
GSK’s Relovair moves into phase III
March 19, 2010Research and Development GlaxoSmithKline, Relovair, Seretide, Theravance, respiratory
GlaxoSmithKline has started phase III asthma trials of Relovair, the respiratory treatment it is developing with San Francisco biopharma firm …
